JPRN-jRCT2031230659尚未招募3 期
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTI-CENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO - Tranquillo LTE
Kawai Norisuke0 个研究点目标入组 400 人开始时间: 2024年2月27日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants >=18 years of age at Screening in Study B7981040. Adolescents (12 to <18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
- •Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
- •The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040
排除标准
- •Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
- •Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With Nonsegmental VitiligoON SEGMENTAL VITILIGOCTIS2023-505804-42-00Pfizer Inc.490
进行中（未招募）
1 期
The aim of the study is to determine how safe and effective PF-04965842 is when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. Patients may also receive topical medications if needed.Moderate to severe atopic dermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-000501-23-ESPfizer Inc., 235 East 42nd Street, New York, NY 100171,370
进行中（未招募）
1 期
The aim of the study is to determine how safe and effective PF-04965842 is when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. Patients may also receive topical medications if needed.Moderate to severe atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-000501-23-DEPfizer Inc., 235 East 42nd Street, New York, NY 100171,235
进行中（未招募）
1 期
The aim of the study is to determine how safe and effective PF-04965842 is when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. Patients may also receive topical medications if needed.Moderate to severe atopic dermatitisMedDRA version: 20.0Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-000501-23-BEPfizer Inc., 235 East 42nd Street, New York, NY 100171,370
进行中（未招募）
1 期
The aim of the study is to determine how safe and effective PF-04965842 is when taken as the treatment for moderate to severe atopic dermatitis in patients aged 12 years or older. Patients may also receive topical medications if needed.Moderate to severe atopic dermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-000501-23-ITPfizer Inc., 235 East 42nd Street, New York, NY 100171,235